Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GANX Stock Alerts

Gain Therapeutics (GANX) Competitors

Gain Therapeutics logo
$1.87 -0.03 (-1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 +0.01 (+0.70%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GANX vs. PALI, SIGA, CABA, CMPX, and RZLT

Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Palisade Bio (PALI), Siga Technologies (SIGA), Cabaletta Bio (CABA), Compass Therapeutics (CMPX), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.

How does Gain Therapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 7.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 417.77%. Gain Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 354.55%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Palisade Bio is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Palisade Bio's return on equity of -47.76% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Palisade BioN/A -47.76% -42.98%
Gain Therapeutics N/A -237.54%-145.96%

Palisade Bio has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palisade Bio$250K1,319.27-$16.78M-$2.12N/A
Gain Therapeutics$50K1,595.11-$20.16M-$0.61N/A

Palisade Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

In the previous week, Palisade Bio had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Palisade Bio and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.05 beat Palisade Bio's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Palisade Bio beats Gain Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Siga Technologies?

Gain Therapeutics (NASDAQ:GANX) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 2.0% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Siga Technologies has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,595.11-$20.16M-$0.61N/A
Siga Technologies$94.57M3.52$23.28M$0.3114.97

Gain Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 354.55%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Gain Therapeutics is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Siga Technologies has a net margin of 24.61% compared to Gain Therapeutics' net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -237.54% -145.96%
Siga Technologies 24.61%11.25%9.98%

Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

In the previous week, Siga Technologies had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Siga Technologies and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.05 beat Siga Technologies' score of 0.67 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Siga Technologies beats Gain Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

12.0% of Gain Therapeutics shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by company insiders. Comparatively, 7.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cabaletta Bio presently has a consensus target price of $17.00, suggesting a potential upside of 309.64%. Gain Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 354.55%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Cabaletta Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Cabaletta Bio's return on equity of -121.73% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -121.73% -90.19%
Gain Therapeutics N/A -237.54%-145.96%

In the previous week, Cabaletta Bio had 6 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for Cabaletta Bio and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.05 beat Cabaletta Bio's score of 0.47 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cabaletta Bio has a beta of 3.18, meaning that its share price is 218% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Gain Therapeutics has higher revenue and earnings than Cabaletta Bio. Gain Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$167.86M-$2.28N/A
Gain Therapeutics$50K1,595.11-$20.16M-$0.61N/A

Summary

Cabaletta Bio beats Gain Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Compass Therapeutics' return on equity of -43.61% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -43.61% -38.05%
Gain Therapeutics N/A -237.54%-145.96%

In the previous week, Compass Therapeutics had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 6 mentions for Compass Therapeutics and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.05 beat Compass Therapeutics' score of -0.34 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Compass Therapeutics currently has a consensus target price of $13.60, suggesting a potential upside of 593.88%. Gain Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 354.55%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Compass Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.

Gain Therapeutics has lower revenue, but higher earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass Therapeutics$850K415.27-$66.49M-$0.43N/A
Gain Therapeutics$50K1,595.11-$20.16M-$0.61N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 29.8% of Compass Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Compass Therapeutics beats Gain Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Rezolute?

Gain Therapeutics (NASDAQ:GANX) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Rezolute had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Rezolute and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.05 beat Rezolute's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rezolute
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rezolute's return on equity of -64.81% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -237.54% -145.96%
Rezolute N/A -64.81%-59.37%

Gain Therapeutics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,595.11-$20.16M-$0.61N/A
RezoluteN/AN/A-$74.41M-$0.93N/A

Gain Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 354.55%. Rezolute has a consensus target price of $8.00, indicating a potential upside of 143.16%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Gain Therapeutics is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Rezolute
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.45

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by insiders. Comparatively, 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Summary

Gain Therapeutics and Rezolute tied by winning 7 of the 14 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GANX vs. The Competition

Export
MetricGain TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$79.76M$3.10B$6.25B$11.87B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio-3.0718.3729.0428.47
Price / Sales1,595.11281.30476.6160.92
Price / CashN/A50.4327.6236.52
Price / Book3.904.339.676.67
Net Income-$20.16M$72.19M$3.55B$332.53M
7 Day Performance1.08%2.03%1.70%2.01%
1 Month Performance1.08%6.42%5.62%9.19%
1 Year Performance-7.88%37.73%34.41%39.59%

Gain Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GANX
Gain Therapeutics
1.66 of 5 stars		$1.87
-1.6%		$8.50
+354.5%		N/A$79.76M$50KN/A20
PALI
Palisade Bio
1.9535 of 5 stars		$1.95
-0.5%		$10.20
+423.1%		N/A$328.15M$250KN/A10
SIGA
Siga Technologies
1.4019 of 5 stars		$4.59
+0.7%		N/AN/A$326.70M$94.57M14.8140
CABA
Cabaletta Bio
2.2628 of 5 stars		$2.86
-1.7%		$17.00
+494.4%		N/A$323.95MN/AN/A50
CMPX
Compass Therapeutics
3.1849 of 5 stars		$1.84
+2.8%		$13.60
+639.1%		N/A$322.36M$850KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel